Pages that link to "Q3950557"
Jump to navigation
Jump to search
The following pages link to sargramostim (Q3950557):
Displayed 50 items.
- Crohn's disease (Q1472) (← links)
- breast cancer (Q128581) (← links)
- melanoma (Q180614) (← links)
- Colony stimulating factor 2 (Q423660) (← links)
- lymphoid leukemia (Q6708277) (← links)
- lymphosarcoma (Q12284921) (← links)
- Hodgkin's lymphoma, mixed cellularity (Q18557991) (← links)
- Sargramostim (GM-CSF) for induction of remission in Crohn's disease (Q24235068) (← links)
- Sargramostim (GM-CSF) for induction of remission in Crohn's disease (Q24235115) (← links)
- Sargramostim for active Crohn's disease (Q28252940) (← links)
- A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression (Q28277632) (← links)
- Perioperative sargramostim (recombinant human GM-CSF) induces an increase in the level of soluble VEGFR1 in colon cancer patients undergoing minimally invasive surgery (Q28303071) (← links)
- Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial (Q30407940) (← links)
- Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group study (Q33367537) (← links)
- Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial (Q33406537) (← links)
- Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma (Q33488800) (← links)
- Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer (Q33497695) (← links)
- Comparative safety of filgrastim versus sargramostim in patients receiving myelosuppressive chemotherapy (Q34113758) (← links)
- Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma (Q36031518) (← links)
- The role of sargramostim (rhGM-CSF) as immunotherapy (Q37015071) (← links)
- A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study (Q37223381) (← links)
- Sargramostim (GM-CSF) for induction of remission in Crohn's disease: a cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials (Q38007115) (← links)
- Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses (Q38046894) (← links)
- Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial. (Q38709455) (← links)
- Biological Effects of Anti-Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Antibody Formation in Patients Treated With GM-CSF (Sargramostim) as Adjuvant Therapy of Melanoma (Q39118074) (← links)
- Objective clinical regression of metastatic breast cancer in disparate sites after use of whole-cell vaccine genetically modified to release sargramostim (Q40234641) (← links)
- Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy (Q40331854) (← links)
- Drug formulary review process for sargramostim and filgrastim: focus on analysis of adverse drug reactions. (Q40385017) (← links)
- Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim (Q40600373) (← links)
- Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells (Q40628003) (← links)
- Randomized trial comparing the tolerability of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in cancer patients receiving myelosuppressive chemotherapy (Q40648751) (← links)
- Inhaled Sargramostim Induces Resolution of Pulmonary Alveolar Proteinosis in Lysinuric Protein Intolerance (Q41009034) (← links)
- Phase I trial of sargramostim in pediatric Crohn's disease (Q42644869) (← links)
- Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia. (Q44070887) (← links)
- Marginal keratitis associated with administration of filgrastim and sargramostim in a healthy peripheral blood progenitor cell donor (Q44072468) (← links)
- High prevalence of unique recombinant forms of HIV-1 in Ghana: molecular epidemiology from an antiretroviral resistance study (Q44095969) (← links)
- Fulminant CNS perivascular lymphocytic proliferation: association with sargramostim, a hematopoietic growth factor. (Q44864781) (← links)
- Sweet's syndrome associated with sargramostim (granulocyte-macrophage colony stimulating factor) treatment (Q44957100) (← links)
- Neutropenia and neoplasia: an overview of the pharmacoeconomics of sargramostim in cancer therapy (Q45107966) (← links)
- Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. (Q45977890) (← links)
- Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma (Q46593196) (← links)
- Sargramostim in patients with Crohn's disease: results of a phase 1-2 study (Q48034825) (← links)
- Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioning. (Q50635378) (← links)
- Management of Mucositis With GM-CSF (Sargramostim) Mouthwash Study Protocol (Q59494137) (← links)
- Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer (Q61978903) (← links)
- Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome (Q61978949) (← links)
- Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma (Q61979949) (← links)
- A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients (Q61980115) (← links)
- Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC) (Q61981344) (← links)
- Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer (Q62025849) (← links)